Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar;26(3):135-146.
doi: 10.1007/s11886-023-02003-4. Epub 2024 Jan 26.

The Expansion of Genetic Testing in Cardiovascular Medicine: Preparing the Cardiology Community for the Changing Landscape

Affiliations
Review

The Expansion of Genetic Testing in Cardiovascular Medicine: Preparing the Cardiology Community for the Changing Landscape

Nosheen Reza et al. Curr Cardiol Rep. 2024 Mar.

Abstract

Purpose of review: Pathogenic DNA variants underlie many cardiovascular disease phenotypes. The most well-recognized of these include familial dyslipidemias, cardiomyopathies, arrhythmias, and aortopathies. The clinical presentations of monogenic forms of cardiovascular disease are often indistinguishable from those with complex genetic and non-genetic etiologies, making genetic testing an essential aid to precision diagnosis.

Recent findings: Precision diagnosis enables efficient management, appropriate use of emerging targeted therapies, and follow-up of at-risk family members. Genetic testing for these conditions is widely available but under-utilized. In this review, we summarize the potential benefits of genetic testing, highlighting the specific cardiovascular disease phenotypes in which genetic testing should be considered, and how clinicians can integrate guideline-directed genetic testing into their practice.

Keywords: Cardiovascular genetics; Genetic testing; Genetics; Inherited heart disease.

PubMed Disclaimer

Conflict of interest statement

N.M, and R.L.A. report no relevant disclosures. J.W.B. owns stock in Illumina, Inc. N.R. reports speaking honoraria from Zoll Inc. and personal fees for the Advisory board from Roche Diagnostics. N.M. reports grant support from Amgen, Ionis, Pfizer, Novartis, AstraZeneca; and personal fees from Beckman Coulter and Amgen; and honoraria/CME program from Medical Education Speakers Network (MESN).

Figures

Fig. 1
Fig. 1
Clinical utilities of cardiovascular genetic testing. Genetic testing supports physician diagnostic and therapeutic decision making and adds important new information of use to patients and their families
Fig. 2
Fig. 2
The genetic testing process. Selection of patients for testing is the most impactful step in the diagnostic process. Resources are available to help with test selection and the clinical interpretation of the test results

References

    1. Lopez Santibanez Jacome L, Dellefave-Castillo LM, Wicklund CA, et al. Practitioners' confidence and desires for education in cardiovascular and sudden cardiac death genetics. J Am Heart Assoc. 2022;11(7):e023763. doi: 10.1161/JAHA.121.023763. - DOI - PMC - PubMed
    1. Directions of Cardiology in the Next Decade: 2022–2032 (Eugene Braunwald, MD) January 13, 2022 [https://www.youtube.com/watch?v=ybMT-9DLMaY].
    1. Beausejour Ladouceur V. Training in cardiovascular genetics. J Am Coll Cardiol. 2015;65(8):856–858. doi: 10.1016/j.jacc.2015.01.003. - DOI - PubMed
    1. Nguengang Wakap S, Lambert DM, Olry A, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28(2):165–173. doi: 10.1038/s41431-019-0508-0. - DOI - PMC - PubMed
    1. Ho CY, Day SM, Ashley EA, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe) Circulation. 2018;138(14):1387–1398. doi: 10.1161/CIRCULATIONAHA.117.033200. - DOI - PMC - PubMed

Publication types